OS Therapies (NYSE American: OSTX) has announced its intent to spin off OS Animal Health (OSAH)—the company’s wholly owned subsidiary developing OST-HER2 for canine osteosarcoma—into a standalone public company listed on a national stock exchange.
The company expects OSAH to become a standalone public company on a U.S. national stock exchange in the first half of 2026.
In a statement, Edward Robb, DVM, animal health strategic advisor for OS, commented, “Having been a part of the effort to improve the standard of care for dogs with osteosarcoma for over a decade, I’m pleased that OS Therapies has made the decision to have the animal health program be housed in a standalone, separately financed venture so that it can receive the attention it deserves. I will be taking on a key senior management position with OSAH and will be working to help recruit the best leadership in the veterinary space to support a successful commercial launch once the product receives the necessary regulatory authorizations to relaunch in the U.S. The veterinary oncology market is expected to grow from $1.5 billion in 2024 to $4.77 billion in 2034, according to Towards Health, driven primarily by the North American market due to its advanced veterinary infrastructure and high expenditure on pet healthcare. We believe that OST-HER2, as a molecularly targeted advanced immunotherapy that likely has potential across all HER2-positive cancers, has the potential to be a significant player in that growth.”
Paul Romness, MPH, chairman and CEO of OS, remarked, “We have spent the last several months engaging with key opinion leaders, regulatory experts, management candidates, potential investors and potential USDA-registered commercial manufacturers, who together would create the critical mass needed to make this standalone animal health venture a success. With a path forward for OST-HER2 in human osteosarcoma based upon the FDA’s August 18, 2025 Draft Regulatory Guidance that outlines the importance of increasing Overall Survival as the overarching efficacy endpoint in oncology clinical trials, we believe it is now prudent to have a separately financed entity bringing the canine version of this product forward.”
Mr. Romness continued, “Given that canine OST-HER2 has previously been conditionally approved by the U.S. Department of Agriculture (USDA) for canine osteosarcoma, and that a seminal publication related to its additional uses in preventing metastatic disease progression and controlling primary disease is forthcoming in the near future, we have a high degree of confidence that USDA will allow OST-HER2 back on the market. We believe it is important for OS Therapies shareholders to end up with direct equity participation in OSAH once it becomes a public company.”
